Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

KYG7487R1002
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00ZS40360
RGC
Regencell Bioscience Holdings
GICS: Health Care · SECTOR: EQTY · SUB-SECTOR: Drug Manufacturers—Specialty & Generic · THEMEFOLIO: $HLTH
NAME
Regencell Bioscience Holdings
ISIN
KYG7487R1002
TICKER
RGC
MIC
XNAS
REUTERS
RGC.OQ
BLOOMBERG
RGC US
So., 03.05.2026       Regencell Bioscience
KYG7487R1002

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regencell To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regencell between October 28, 2024 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi part...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
So., 03.05.2026       Regencell Bioscience
KYG7487R1002

New York, New York--(Newsfile Corp. - May 2, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"). A class action lawsuit has alre...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Sa., 02.05.2026       Regencell Bioscience
KYG7487R1002

New York, New York--(Newsfile Corp. - May 1, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"). A class action lawsuit has already b...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Regencell Bioscience
KYG7487R1002

New York, New York--(Newsfile Corp. - May 1, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleged...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Fr., 01.05.2026       Regencell Bioscience
KYG7487R1002

NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC) and certain officers.   The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is o...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Regencell Bioscience
KYG7487R1002

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Regencell Bioscience
KYG7487R1002

Law Offices of Howard G. Smith announces an investigation on behalf of Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC), CONTACT THE LAW OFF...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Do., 30.04.2026       Regencell Bioscience
KYG7487R1002

New York, New York--(Newsfile Corp. - April 29, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"). A class action lawsuit has a...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Regencell Bioscience
KYG7487R1002

The Law Offices of Frank R. Cruz announces an investigation of Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON REGENCELL BIOSCIENCE HOLDINGS LIMITED (RGC), CLICK HERE TO INQUIRE A...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Regencell Bioscience
KYG7487R1002

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Regencell To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Regencell between October 28, 2024 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi part...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 29.04.2026       Regencell Bioscience
KYG7487R1002

NEW YORK, April 29, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Regencell Bioscience Holdings Limited ("Regencell Bioscience Holdings Limited" or the "Company") (NASDAQ: RGC) of a class action securities lawsuit....
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Mi., 29.04.2026       Regencell Bioscience
KYG7487R1002

New York, New York--(Newsfile Corp. - April 28, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Regencell Bioscience Holdings Limited (NASDAQ: RGC) between October 28, 2024 and October 31, 2025, inclusive (the "Class Period"). A class action lawsuit has alread...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Regencell Bioscience
KYG7487R1002

New York, New York--(Newsfile Corp. - April 28, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and certain of its officers.This lawsuit seeks to recover damages against Defendants for alleg...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Regencell Bioscience
KYG7487R1002

SAN DIEGO, April 27, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Di., 28.04.2026       Regencell Bioscience
KYG7487R1002

Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell is a purported early-stage bioscience company. For more information, s...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Sa., 25.04.2026       Regencell Bioscience
KYG7487R1002

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercializatio...
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink
Do., 20.11.2025       Regencell Bioscience
KYG7487R1002

NEW YORK, Nov. 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Regencell Bioscience Holdings Limited ("Regencell" or the "Company") (NASDAQ: RGC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Zur Nachricht
Regencell Bioscience
Charts & Research Termsheets Terminal
Permalink